Deals, Mergers and Acquisitions, and Licensing - Pharmaceutical Executive

ADVERTISEMENT

Deals
Mergers, acquisitions, strategic partnerships, and product licensing. Plus, strategies and tactics for better deal-making

2013 Dealmakers Outlook

April 1, 2013

Pharm Exec's annual look at the trends and best practices in biopharm licensing and M&A for the year ahead.

Safeguarding the Value of Patent Assets

March 1, 2013

As small biotech firms test the water in partnerships with Big Pharma, the best calling card is a well-framed strategy on intellectual property.

Transforming Drug Development: A Lilly–Covance Case Study

December 1, 2012

Eli Lilly's pioneering pact with leading CRO Covance made big news when it happened. Four years later, both parties can point to metrics that suggest the benefit is mutual.

2012 Dealmakers Outlook

June 1, 2012

Pharm Exec convened a panel of heavy hitters in business development to crack the bat on best practices in licensing and M&A for the year ahead.

Pharm Exec's 2012 Pipeline Report

December 1, 2011

It's a neck and neck race toward safer, faster, and medically superior treatments. Which organizations have what it takes to jockey their products into the winner's circle?

30 Years of Pharma: Perspective in Numbers, Part 3

October 1, 2011

Top 10 Companies by Market Share

30 Years of Pharma: Perspective in Numbers, Part 1

October 1, 2011

Top 10 Products Worldwide

30 Years of Pharma: Perspective in Numbers, Part 2

October 1, 2011

30 Years of Pharma: Perspective in Numbers

Pharm Exec's 10th Annual Industry Audit

September 1, 2011

Bill Trombetta surveys the landscape of pharma financials over the past year, and shows which companies rode the wave to the top of the industry in delivering value to shareholders.

ADVERTISEMENT

Click here